down arrow

AbCellera Biologics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA00288U1066
USD
3.65
0.19 (5.49%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Dynavax Technologies Corp.
Zentalis Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
AbCellera Biologics, Inc.
Alvotech
Beam Therapeutics, Inc.
Arcellx, Inc.
Recursion Pharmaceuticals, Inc.
Nuvalent, Inc.
Rocket Pharmaceuticals, Inc.
Ventyx Biosciences, Inc.
Why is AbCellera Biologics, Inc. ?
1
The company has declared Negative results for the last 10 consecutive quarters
  • ROCE(HY) Lowest at -15.64%
  • DEBT-EQUITY RATIO (HY) Highest at -43.29 %
  • DEBTORS TURNOVER RATIO(HY) Lowest at 0.3 times
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 22.71%, its profits have fallen by -14.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is AbCellera Biologics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
AbCellera Biologics, Inc.
25.43%
0.04
77.40%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-47.94%
EBIT Growth (5y)
-193.75%
EBIT to Interest (avg)
-96.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.05
Tax Ratio
20.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
51.28%
ROCE (avg)
43.54%
ROE (avg)
8.32%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.71
EV to EBIT
-0.32
EV to EBITDA
-0.45
EV to Capital Employed
0.26
EV to Sales
4.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-81.17%
ROE (Latest)
-16.41%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -79.94 MM

NET PROFIT(HY)

Higher at USD -80.35 MM

RAW MATERIAL COST(Y)

Fallen by -113.72% (YoY

NET SALES(Q)

Highest at USD 17.08 MM

OPERATING PROFIT(Q)

Highest at USD -42.53 MM

OPERATING PROFIT MARGIN(Q)

Highest at -248.92 %

PRE-TAX PROFIT(Q)

Highest at USD -36.34 MM

-7What is not working for the Company
ROCE(HY)

Lowest at -15.64%

DEBT-EQUITY RATIO (HY)

Highest at -43.29 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.3 times

Here's what is working for AbCellera Biologics, Inc.
Net Sales
At USD 17.08 MM has Grown at 133.29%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Operating Cash Flow
Highest at USD -79.94 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -80.35 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Sales
Highest at USD 17.08 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD -42.53 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at -248.92 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD -36.34 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Raw Material Cost
Fallen by -113.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for AbCellera Biologics, Inc.
Debt-Equity Ratio
Highest at -43.29 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 0.3 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."